NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis $7.51 +0.46 (+6.52%) Closing price 04:00 PM EasternExtended Trading$7.55 +0.04 (+0.59%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immatics Stock (NASDAQ:IMTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immatics alerts:Sign Up Key Stats Today's Range$6.94▼$7.6150-Day Range$6.73▼$9.7552-Week Range$6.65▼$12.41Volume1.49 million shsAverage Volume539,125 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$19.67Consensus RatingModerate Buy Company Overview Immatics N.V. (NASDAQ: IMTX) is a biotechnology company focused on developing T cell receptor (TCR)-based therapies for the treatment of cancer. The company identifies cancer targets and designs treatments intended to direct a patient’s immune system toward tumor cells, including solid tumors that may be difficult to address with conventional immunotherapies. Immatics’ technology platforms support several therapeutic approaches, including TCR-engineered T-cell therapies and TCR-based bispecific molecules that can engage both cancer targets and T cells. Its product pipeline has included candidates directed at targets such as PRAME, a tumor-associated antigen expressed in multiple cancers. The company also uses its target-discovery and validation platforms to identify and evaluate cancer antigens for potential drug development. Founded in 2000 and headquartered in Tübingen, Germany, Immatics has expanded its operations internationally, including a presence in the United States. The company develops therapies independently and through collaborations with pharmaceutical and biotechnology partners. Immatics is led by Chief Executive Officer Harpreet Singh, who has been associated with the company since its early development.AI Generated. May Contain Errors. Read More Immatics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreIMTX MarketRank™: 3.545539033455 of 5 starsImmatics scored higher than 71% of companies evaluated by MarketBeat, and ranked 209th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingImmatics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmatics has a consensus price target of $19.67, representing about 161.9% upside from its current price of $7.51.Amount of Analyst CoverageImmatics has only been the subject of 2 research reports in the past 90 days.Read more about Immatics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Immatics are expected to decrease in the coming year, from ($1.99) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -4.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immatics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.79% of the float of Immatics has been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 4.15.Change versus previous monthShort interest in Immatics has recently decreased by 16.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.15 News SentimentImmatics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immatics this week, compared to 2 articles on an average week.Search Interest4 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $7,499,991.00 in company stock, which represents 0.7306% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,499,991.00 in company stock and sold $0.00 in company stock.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immatics' insider trading history. Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMTX Stock News HeadlinesImmatics (NASDAQ:IMTX) Sets New 12-Month Low - Time to Sell?October 17 at 4:03 AM | americanbankingnews.comStifel initiates coverage of Immatics NV at buyOctober 14, 2026 | msn.comBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle is set to begin by October 20. Brown has built a new model portfolio featuring five AI plays tied to this pattern, which he says has repeated with a track record of success in the past. He notes this cycle unfolds outside the traditional stock market, combined with the ongoing AI boom.October 20 at 1:00 AM | Brownstone Research (Ad)Immatics (NASDAQ:IMTX) Sets New 12-Month Low - Here's What HappenedOctober 9, 2026 | americanbankingnews.comImmatics and 4 more stocks see action from activist investorsSeptember 4, 2026 | msn.comImmatics Raises $161 Million in Completed Equity Offering to Advance PRAME Cancer ProgramsAugust 26, 2026 | tipranks.comImmatics N.v Share Price (IMTX.US)August 25, 2026 | lse.co.ukImmatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal MelanomaAugust 25, 2026 | seekingalpha.comSee More Headlines IMTX Stock Analysis - Frequently Asked Questions How have IMTX shares performed this year? Immatics' stock was trading at $10.50 at the beginning of 2026. Since then, IMTX stock has decreased by 28.5% and is now trading at $7.51. How were Immatics' earnings last quarter? Immatics N.V. (NASDAQ:IMTX) announced its quarterly earnings data on Tuesday, August, 18th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.47) by $0.06. The firm earned $10.44 million during the quarter, compared to analysts' expectations of $12.42 million. Immatics had a negative net margin of 495.71% and a negative trailing twelve-month return on equity of 47.41%. Who are Immatics' major shareholders? Top institutional shareholders of Immatics include Doliver Advisors LP (0.02%). View institutional ownership trends. How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Editas Medicine (EDIT), Gilead Sciences (GILD), NVIDIA (NVDA), Citigroup (C), Salesforce (CRM), IonQ (IONQ) and NIO (NIO). Company Calendar Last Earnings8/18/2026Today10/20/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, IMTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMTX CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees704Year FoundedN/APrice Target and Rating Average Price Target for Immatics$19.67 High Price Target$25.00 Low Price Target$15.00 Potential Upside/Downside+161.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$222.26 million Net Margins-495.71% Pretax Margin-495.98% Return on Equity-47.41% Return on Assets-39.45% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual Sales$54.60 million Price / Sales18.80 Cash FlowN/A Price / Cash FlowN/A Book Value$4.09 per share Price / Book1.84Miscellaneous Outstanding Shares136,690,000Free FloatN/AMarket Cap$1.03 billion OptionableOptionable Beta1.36 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:IMTX) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
